Outcome measures for chronic inflammatory demyelinating polyneuropathy in research: relevance and applicability to clinical practice

Yusuf A Rajabally*, Farzad Fatehi

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropathy (CIDP). Various scales have been proposed in recent years, some now commonly utilized in daily clinical practice. The available evidence base relies itself on randomized controlled trial data obtained over the past 30 years, with several studies using different primary and secondary outcomes. We here review the different outcome measures used in CIDP research in relation to those currently recommended for clinical management. We consider the evidence base for CIDP treatment from the primary and secondary outcomes used in these studies and attempt to assess how this may relate to current clinical practice of routine evaluation of treatment effects and long-term monitoring.
Original languageEnglish
Pages (from-to)259-266
Number of pages8
JournalNeurodegenerative disease management
Volume9
Issue number5
DOIs
Publication statusPublished - 3 Oct 2019

Bibliographical note

For full bibliographic citation, please refer to the version available at www.futuremedicine.com; https://www.futuremedicine.com/doi/abs/10.2217/nmt-2019-0009?journalCode=nmt

Keywords

  • chronic inflammatory demyelinating polyneuropathy
  • clinical practice
  • outcome measures

Fingerprint

Dive into the research topics of 'Outcome measures for chronic inflammatory demyelinating polyneuropathy in research: relevance and applicability to clinical practice'. Together they form a unique fingerprint.

Cite this